Abstract
Therapeutic antibodies are implicated into the very promising and fast growing area of pharmaceutics. Human hybridoma technology, allowing generation of natural human antibodies in a native form, seems to be the most direct way that require no additional modifications for production of therapeutic antibodies. However, technical difficulties in human hybridoma creation discovered in the 80s of the last century have switched the mainstream therapeutic antibody development into new directions like display and transgenic mice techniques. These approaches have provided remarkable achievements in antibody engineering within last 15 years, but also revealed other limitations. Thus, it is time to turn back to forgotten human hybridoma technology. In this review, we describe new advances in all components of human hybridoma technology and discuss challenges in generating novel therapeutic mABs based on hybridoma technologies.
Keywords: Therapeutic antibodies, hybridoma, fusion partner, B cells, EBV transformation, miR transformation.
Current Pharmaceutical Design
Title:Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique
Volume: 22 Issue: 7
Author(s): Xenia A. Glukhova, Olga V. Prusakova, Julia A. Trizna, Michael M. Zaripov, Gaida V. Afanas’eva, Anatoly S. Glukhov, Rimma A. Poltavtseva, Alexei A. Ivanov, Marco Avila-Rodriguez, George E. Barreto, Gjumrakch Aliev and Igor P. Beletsky
Affiliation:
Keywords: Therapeutic antibodies, hybridoma, fusion partner, B cells, EBV transformation, miR transformation.
Abstract: Therapeutic antibodies are implicated into the very promising and fast growing area of pharmaceutics. Human hybridoma technology, allowing generation of natural human antibodies in a native form, seems to be the most direct way that require no additional modifications for production of therapeutic antibodies. However, technical difficulties in human hybridoma creation discovered in the 80s of the last century have switched the mainstream therapeutic antibody development into new directions like display and transgenic mice techniques. These approaches have provided remarkable achievements in antibody engineering within last 15 years, but also revealed other limitations. Thus, it is time to turn back to forgotten human hybridoma technology. In this review, we describe new advances in all components of human hybridoma technology and discuss challenges in generating novel therapeutic mABs based on hybridoma technologies.
Export Options
About this article
Cite this article as:
Glukhova A. Xenia, Prusakova V. Olga, Trizna A. Julia, Zaripov M. Michael, Afanas’eva V. Gaida, Glukhov S. Anatoly, Poltavtseva A. Rimma, Ivanov A. Alexei, Avila-Rodriguez Marco, Barreto E. George, Aliev Gjumrakch and Beletsky P. Igor, Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique, Current Pharmaceutical Design 2016; 22 (7) . https://dx.doi.org/10.2174/1381612822666151223102845
DOI https://dx.doi.org/10.2174/1381612822666151223102845 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
INNO-206 (DOXO-EMCH), an Albumin-Binding Prodrug of Doxorubicin Under Development for Phase II Studies
Current Bioactive Compounds NOTCH Signaling as a Novel Cancer Therapeutic Target
Current Cancer Drug Targets SANTAVAC ™: A Novel Universal Antigen Composition for Developing Cancer Vaccines
Recent Patents on Biotechnology Antisense Treatment in Human Prostate Cancer and Melanoma
Current Cancer Drug Targets Apoptotic Potency of Angiostatic Compounds in the Treatment of Cancer
Current Pharmaceutical Biotechnology Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews De Novo Malignancies After Organ Transplantation: Focus on Viral Infections
Current Molecular Medicine A Review on Novel Breast Cancer Therapies: Photodynamic Therapy and Plant Derived Agent Induced Cell Death Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Molecular Signals Elicited by GPCR Agonists in Hypertension, Cardiovascular Remodeling: Are MMPs and ADAMs Elusive Therapeutic Targets?
Current Hypertension Reviews Pisosterol Induces G2/M Cell Cycle Arrest and Apoptosis via the ATM/ATR Signaling Pathway in Human Glioma Cells
Anti-Cancer Agents in Medicinal Chemistry The Redox Regulation of Thiol Dependent Signaling Pathways in Cancer
Current Pharmaceutical Design Phosphorothioate Oligonucleotides: Effectiveness and Toxicity
Current Drug Targets Anticancer Drugs in Liposomal Nanodevices: A Target Delivery for a Targeted Therapy
Current Topics in Medicinal Chemistry RNA G-Quadruplex: The New Potential Targets for Therapy
Current Topics in Medicinal Chemistry Dendrimer-drug Conjugates in Drug Delivery and Targeting
Pharmaceutical Nanotechnology Radiopharmaceuticals in Tumor Hypoxia Imaging: A Review Focused on Medicinal Chemistry Aspects
Anti-Cancer Agents in Medicinal Chemistry Novel Colchicine Derivatives and their Anti-cancer Activity
Current Topics in Medicinal Chemistry Aptamers: Potential Applications to Pancreatic Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Characterization of Molecular and Functional Alterations of Tumor Endothelial Cells to Design Anti-Angiogenic Strategies
Current Vascular Pharmacology Circadian Timekeeping in Anticancer Therapeutics: An Emerging Vista of Chronopharmacology Research
Current Drug Metabolism